The combination of dehydroepiandrosterone, transdermal testosterone, and growth hormone as an adjuvant therapy in assisted reproductive technology cycles in patients aged below 40 years with diminished ovarian reserve
2015 ◽
Vol 12
(2)
◽
pp. 60-65
◽
2013 ◽
Vol 99
(2)
◽
pp. 382-388.e7
◽
2014 ◽
Vol 102
(3)
◽
pp. e221-e222
◽
2020 ◽
Vol 114
(1)
◽
pp. 118-124.e1
◽
2021 ◽
Vol 50
(2)
◽
pp. 101982
2019 ◽
pp. 1
◽
2015 ◽
Vol 104
(3)
◽
pp. 612-619.e3
◽